CeriBell, Inc. (CBLL)

NASDAQ: CBLL · Real-Time Price · USD

26.92

+0.19 (0.71%)

Dec 20, 2024, 4:00 PM EST - Market closed

0.71% (1D)

Market Cap	964.39M
Revenue (ttm)	60.04M
Net Income (ttm)	-36.15M
Shares Out	35.82M
EPS (ttm)	-6.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	530,394
Open	26.34
Previous Close	26.73
Day's Range	26.00 - 28.23
52-Week Range	23.00 - 32.75
Beta	n/a
Analysts	Strong Buy
Price Target	33.25 (+23.51%)
Earnings Date	Feb 14, 2025

About CBLL

CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, ... [Read more]

Industry Medical Devices

Sector Healthcare

IPO Date Oct 11, 2024

Employees 229

Stock Exchange NASDAQ

Ticker Symbol CBLL

Website https://ceribell.com

Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for CBLL stock is "Strong Buy." The 12-month stock price forecast is $33.25, which is an increase of 23.51% from the latest price.

Price Target

$33.25

(23.51% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

CeriBell: Healthcare Technology Stock With A Promising Growth Outlook

Initiating coverage on CeriBell with a "Buy" rating, citing a promising growth outlook and a 24-month investment horizon. CeriBell's Ceribell System, an AI-powered EEG platform, shows strong revenue g...

4 weeks ago - Seeking Alpha

Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with seri...

6 weeks ago - GlobeNewsWire

Ceribell to Report Third Quarter 2024 Financial Results on November 12, 2024

SUNNYVALE, Calif. , Oct. 29, 2024 /PRNewswire/ -- Ceribell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical technology company focused on transforming the diagnosis and management of pati...

7 weeks ago - PRNewsWire

CeriBell: An Interesting EEG Play Going Public

CeriBell's IPO was highly successful, with shares rising 60%, but I'm cautious about investing after such a significant price increase. The company offers a revolutionary EEG platform for neurological...

2 months ago - Seeking Alpha

New Clinical Evidence Links Ceribell Point-of-Care EEG to Shorter Hospital Stays and Better Functional Outcomes Compared to Conventional EEG

—Five abstracts presented at the 2024 Neurocritical Care Society Annual Meeting demonstrated the clinical impact of the FDA-cleared Ceribell System and Ceribell's AI-powered Clarity™ algorithm— —Clari...

2 months ago - PRNewsWire

CeriBell, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

SUNNYVALE, Calif. , Oct. 15, 2024 /PRNewswire/ -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical technology company focused on transforming the diagnosis and management of pati...